Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
07:00am, Thursday, 01'st Jul 2021
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement wit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Kö
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
11:48am, Tuesday, 01'st Jun 2021
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic desi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage cli
Seres Therapeutics' SER-287 Is Likely To Succeed In Its Phase 2b Trial
03:25pm, Thursday, 18'th Mar 2021
Fecal microbiota transplantation has succeeded in various randomized ulcerative colitis trials.
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
07:00am, Friday, 12'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Op
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript
11:06am, Tuesday, 02'nd Mar 2021
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
09:05am, Tuesday, 02'nd Mar 2021
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
07:00am, Tuesday, 02'nd Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
08:00am, Friday, 26'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor confer
Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline
01:42pm, Monday, 22'nd Feb 2021
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4D Pharma: Impressive Immuno-Oncology Data
06:00pm, Tuesday, 16'th Feb 2021
4D Pharma: Impressive Immuno-Oncology Data
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 06'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, J
5 Medical Outperformers That Might Lose Steam in 2021
10:32am, Tuesday, 22'nd Dec 2020
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
